RLMD Valuation
Relmada Therapeutics Inc
$
0.597
- Overview
- Forecast
- Valuation
RLMD Relative Valuation
RLMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RLMD is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for RLMD's competitors is 0.38, providing a benchmark for relative valuation. Relmada Therapeutics Inc Corp (RLMD) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
People Also Watch
AMZN
Amazon.com Inc
204.070
USD
-1.01%
TSLA
Tesla Inc
343.820
USD
+0.51%
AAPL
Apple Inc
206.860
USD
-0.92%
NVDA
NVIDIA Corp
134.380
USD
-0.88%
META
Meta Platforms Inc
637.100
USD
-0.52%
MSFT
Microsoft Corp
458.170
USD
-0.15%
AVGO
Broadcom Inc
231.680
USD
+0.46%
XOM
Exxon Mobil Corp
104.950
USD
-1.43%
ORCL
Oracle Corp
160.310
USD
+0.42%
WMT
Walmart Inc
97.800
USD
-0.33%
FAQ
Is Relmada Therapeutics Inc (RLMD) currently overvalued or undervalued?
Relmada Therapeutics Inc (RLMD) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.01. The fair price of Relmada Therapeutics Inc (RLMD) is between to according to relative valuation methord.
What is Relmada Therapeutics Inc (RLMD) fair value?
How does RLMD's valuation metrics compare to the industry average?
What is the current P/B ratio for Relmada Therapeutics Inc (RLMD) as of May 21 2025?
What is the current FCF Yield for Relmada Therapeutics Inc (RLMD) as of May 21 2025?
What is the current Forward P/E ratio for Relmada Therapeutics Inc (RLMD) as of May 21 2025?